Could stem cells help newly diagnosed type 1 diabetes patients?
NCT ID NCT00690066
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether infusions of PROCHYMAL, a stem cell product, could safely help people recently diagnosed with type 1 diabetes. The study enrolled 63 participants aged 12–35 who had been diagnosed within the past 20 weeks. Researchers measured how well the pancreas still made insulin and tracked daily insulin use and blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PROCHYMAL (adult stem cells from bone marrow)
What this could lead to
If it works, this could help people with new-onset type 1 diabetes keep making some of their own insulin, reducing daily insulin shots.
What could go wrong
This is a small, early-phase trial (63 people). Stem cell treatments are complex and may not work for everyone. Risks include infusion reactions or no benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AM Diabetes & Endocrinology Center
Bartlett, Tennessee, 38133, United States
-
American Health Research, Inc.
Charlotte, North Carolina, 28207, United States
-
Clinical and Transitional Science Institute
Milwaukee, Wisconsin, 53226, United States
-
Cumberland Valley Endocrinology
Carlisle, Pennsylvania, 17015, United States
-
Desert Endocrinology CRC
Henderson, Nevada, 89052, United States
-
Diabetes Research Institute
Miami, Florida, 33136, United States
-
Nevada Alliance Against Diabetes
Las Vegas, Nevada, 89101, United States
-
Optimum Clinical Research, Inc.
Salt Lake City, Utah, 84102, United States
-
Providence Health Partners - Center for Clinical Research
Dayton, Ohio, 45439, United States
-
Scripps Whittier Diabetes Institute
La Jolla, California, 92037, United States
-
Stanford University
Stanford, California, 94305, United States
-
The Lindner Clinical Trial Center
Cincinnati, Ohio, 45219, United States
-
The Strelitz Diabetes Center, Eastern VA Medical School
Norfolk, Virginia, 23510, United States
-
The University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Alabama, Division of Endocrinology & Metabolism
Birmingham, Alabama, 35294, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Kentucky
Lexington, Kentucky, 40502, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of North Carolina Diabetes Care Center
Chapel Hill, North Carolina, 27599, United States
-
University of Wisconsin Health- West Clinic
Madison, Wisconsin, 53717, United States